September 24 – 26 | Boston, MA
Defining Digital Therapeutics Integration into Healthcare
Partners
Partners
Partners
DTx in 60 seconds
Key Numbers of DTx East
300
Attendees
Join over 300 senior leaders from DTx companies, pharma, investors, payers and HCP’s at the meeting point of the digital therapeutics industry.
50+
Expert Speakers
Hear from the pioneers and decision-makers from across healthcare as they decipher the leading opportunities for digital therapeutics integration.
15
Hours of Networking
Brand new networking-specific sessions including speed networking, dedicated 1-2-1 meeting time and more will provide more opportunities for you to meet the experts and future collaborators.
What are Industry Leaders saying about DTx
“The DTx Series is my go-to place for staying up-to-date and meeting all of the key players in this promising new digital health category.”
– Bozidar Jovecevic, VP, Global Head of Digital Therapeutics
Sanofi
“I am excited to attend DTx for the fourth time. Whether as a presenter or part of the audience, I learn so much from other Digital Therapeutic executives and attendees about topics ranging from clinical trials to commercialization and everything in between!”
– Debra Reisenthel, Founding CEO
Palo Alto Health Sciences
“I have been to the two editions of DTx West and I’m looking forward to attending DTx East this year. The conference brings together key leaders from across the digital health space to discuss new ideas and ongoing trends that are useful takeaways to bring back to my team.”
– Pablo Pantaleoni, VP & General Manager
Headspace Health
Expert Speaker Faculty
Elli Kaplan is the co-founder and CEO of Neurotrack. Her career spans two decades in the public and private sectors, including at the White House, the State and Treasury Departments, and the United Nations Development Program. Elli has also held positions with AIG, Goldman Sachs and multiple startups. She has won SXSW’s best new startup and DEMO God awards, the J&J World Without Disease Challenge, and presented at TEDx, TechCrunch Disrupt, the Royal Society of Medicine, Wired and the New York Times. Elli has an M.B.A. from Harvard Business School.
Zack Lynch is a Managing Partner and co-founder of JAZZ Venture Partners, a San Francisco-based early stage venture capital firm focused on investing in human performance technology. He is an entrepreneur and futurist who brings a rich understanding of the forces driving the convergence of digital technologies and neuroscience and how new products and services are emerging to unlock human potential across health, wellness, learning, training, sports, enterprise and entertainment. He is the author of the best selling book The Neuro Revolution: How Brain Science Is Changing our World (St. Martin’s Press) which takes a 50 year view on how neuroscience will transform human society. Zack loves to snow board and spend time with his wife and kids.
Adam Kaufman is a health pioneer, having led the building of digital behavior change programs used by dozens of healthcare organizations and tens of thousands of consumers. A health economist, engineer and company executive, Adam speaks to audiences nationwide on the accelerating trend of chronic illness, its impact on lives and costs of care and proven approaches to arresting disease trajectories.
Recognized as a leader in patient engagement and population health, Canary Health works with health plans such as Kaiser Permanente, Humana, GEHA and Blue Shield of California to empower members to better health self-management.
Recognized as a leader in patient engagement and population health, Canary Health works with health plans such as Kaiser Permanente, Humana, GEHA and Blue Shield of California to empower members to better health self-management.
Pavan Choksi is an Investment Associate at Arkitekt Ventures, an early stage healthcare venture fund based in New York City that specializes in investments in novel models of healthcare delivery including digital therapeutics and applications of frontier technology such as artificial intelligence, augmented reality, genomics, and brain machine interfaces to medicine.
Prior to Arkitekt, he was the first employee and Vice President of Corporate Development for Rx.Health, a venture-backed Mount Sinai Health System spin-off commercializing a novel Digital Medicine prescription and delivery platform. As an active member of the digital health ecosystem, he serves as Strategic Advisor to the Digital Therapeutics Alliance and NODE Health.
Passionate about building great products with great user experience! I’m also passionate about Digital Health and value-driven healthcare.
I'm lucky spending all my time bringing this world together as the CEO of DarioHealth Corp. (NASDAQ: DRIO) a leading global digital therapeutics company revolutionizing the way people manage their health across the chronic condition spectrum. By delivering evidence-based interventions that are driven by accumulated data, high-quality software and coaching, we developed a novel approach that empowers individuals to adjust their lifestyle in a personalized way.
Already the highest rated diabetes solution by more than tens of thousands of consumers who love the user-centered approach, DarioHealth is rapidly moving into new chronic conditions and geographic markets.
Jo is fascinated by the convergence of mobile technology and behavioral science, especially surrounding the area of healthcare. At 2Morrow, Jo leads the research and program development efforts to make evidence-based behavior modifications programs more accessible by putting them directly in the hands of those who need them via their smartphones. Focused on drivers that affect chronic disease (i.e. smoking, weight, stress, chronic pain management), 2Morrow's evidence-based platform makes it easier and more convenient to include behavioral science into existing health care treatment plans. 2Morrow distributes programs distributed via employers, wellness platforms, health plans, providers and public health. Jo is a past ``40 under 40`` who started her career as a nurse and has worked in healthcare, education and technologies companies.
Dr. Parks’ research focuses on self-help methods for increasing well-being via books and digital technology. She is Chief Scientist for tech startup Happify, which brings the cutting edge in research-based well-being interventions to large businesses, health plans, and consumers. Her research spans across the whole spectrum of wellness, from non-distressed consumers to stressed employees, sufferers of chronic health conditions, and individuals with depression and/or anxiety. She works to pioneer new methodology in the study of digital therapeutics, especially when it comes to outcomes assessment. Her work has been published in peer-reviewed journals, and in addition to editing three books, she is also an Associate Editor at the Journal of Positive Psychology.
Jeffrey has over 10 years’ experience in healthcare services/operations, market access, reimbursement, and HEOR. Jeffrey has worked both on the industry and consulting side of pharmaceuticals, medical devices, and diagnostics. His previous experience includes global work in the US, EU, and select APAC markets, covering 30 different products. Most recently he served as the Value Development Lead for The Medicines Company and their surgery/perioperative products. He was responsible for a value and evidence based approach to access and commercialization. He graduated from Boston University with a Bachelor of Health Sciences, Master of Science in Physical Therapy, and a Master of Business Administration.
Timothy Aungst, PharmD is an Associate Professor of Pharmacy Practice at MCPHS University, Worcester, MA. He graduated from Wilkes University Nesbitt School of Pharmacy, Wilkes-Barre, PA, in 2011. Afterwards, he pursued a PGY-1 Pharmacy Practice Residency at St. Luke's University Hospital, Bethlehem, PA, with an emphasis on Internal Medicine, Cardiology, and Geriatric Care. He then completed a fellowship program focused on geriatic care, Medicare/Medicaid and drug management, and academia. While completing his post-grad training, he started writing for multiple companies on mHealth and Digital Health, with a focus on mobile apps. Since then, he has conducted research on digital health technologies in the pharmacy space and published in multiple peer review journals and spoken at multiple venues on the topic. He hopes to inspire the pharmacy profession to further integrate digital health into patient care and raise awareness on the future possibilities posed in the coming decades.
Yvonne Yu-Feng Chan, MD, PhD, FACEP is the Director of the Center for Digital Health at the Icahn Institute of Mount Sinai. She is a national leader in digital medicine research and a board-certified Emergency physician. The mission of her Digital Health Center is to drive large-scale participation of patients in biomedical research and clinical care, by leveraging the latest digital technology and advanced analytic techniques to uncover novel insights and actionable results.
Debra is founding CEO of Palo Alto Health Sciences, a digital therapeutic company providing evidence-based, at-home, drug-free solutions in behavioral health. Freespira® is an FDA-cleared treatment for panic disorder, panic attacks and PTSD. Debra has broad operational and leadership experience in start- ups, corporate and nonprofit organizations. Prior to PAHS, Debra worked with a Bay Area incubator to develop a women’s health product, was founding CEO of Novasys Medical, and was VP/GM of a Division of Tyco, inc. (Mallinckrodt, Nellcor). Debra holds a B.A., MBA and R.R.T credentials. She has been a guest entrepreneur for 5 years as part of an HBS case study. Given her deep knowledge of digital therapeutics and medical devices, she is now an Advisor to DTxCC and a Consultant in this growing market.
Pierre Leurent, CEO and founder of VOLUNTIS, has more than 19 years of international experience in digital health in the United States and Europe. Voluntis’ mission is to improve the real-world value of therapies by providing patients and clinicians with therapeutic companion software. Its clinical-grade, regulatory-cleared mobile and cloud solutions embed advanced real-time decision support algorithms to enable patients to better manage their treatment in remote collaboration with their healthcare team. Prior to starting Voluntis in 2001, Pierre worked at GE Medical Systems, where he took part in the development of medical imaging software. He also occupied several positions at HealthCenter Internet Services, a San Francisco-based vendor of electronic medical record solutions.
André is an experienced startup executive, business and sales manager, leader, and strategist. He is an expert in inside and field sales management, pharmaceutical and medical products marketing and sales, commercial strategy planning, and healthcare topics. He has extensive knowledge in B2B and B2C business, software and hardware product portfolios and offerings in the US and Germany. His passion for the impact technology can have on a large scale has been the red thread throughout his career. André holds doctorates from the University of Würzburg in medicine and the University of Freiburg in dental medicine.
André joined Sandoz in June 2018 from his role as CSO at Thermondo GmbH, an integrated energy company offering state-of-the-art energy efficiency services and applying digital process excellence and quality management. This year, The Financial Times named Thermondo #2 fastest growing company in Europe as well as one of the 100 most influential clean-tech companies in the world.
Before that, André was Vice President of Local Sales at Zocdoc, Inc. Zocdoc is an online service that identifies in-network neighborhood physicians, books appointments, shares patient reviews, provides appointment and check-up reminders, and automatically fills in paperwork. Zocdoc is free for patients and available across the United States.
Chihiro leads business development and manages relationship with partner venture capitals for Rx+ Business in Astellas. Rx+ is a concept of new healthcare solution created by combining innovative new technology in different field and Astellas capabilities developed in pharma business. In her role, Chihiro actively seeks partnership and investment opportunities in the growing field of Rx+ business, with high focus in digital health and medical device. Chihiro has 15 years of industry experiences in research and Business Development in addition to Rx+ business. She received an MSc from Waseda University and an MBA from Tsukuba University.
Bakul Patel is Director for Division of Digital Health, at the Center for Devices and Radiological Health (CDRH), at the Food and Drug Administration (FDA). Mr. Patel is responsible for providing leadership, development, implementing, execution, management and setting strategic direction and regulatory policy and coordinate scientific efforts for digital health, software and emerging technologies.
This includes responsibilities in leading the development on policies for mobile health, health information technology, cyber security, medical device interoperability, and medical device software.
Mr. Patel also led the creation of the globally harmonized regulatory framework for “software as a medical device” (SaMD) at the International Medical Device Regulators Forum (IMDRF). The concepts, principles and vocabulary created in harmonized regulatory framework has been used as a foundation in the European union, Japan, Canada, Brazil, Australia and USFDA.
Mr. Patel is the FDA liaison between the Federal Communications Commission (FCC) and the Office of the National Coordinator (ONC).
Mr. Patel is currently leading the effort for the agency in developing an innovative software precertification program in collaboration with all stakeholders to reimagine a regulatory approach for Digital health that that aims for patients and providers to have timely access to safe and effective digital health products.
Prior to joining FDA, Mr. Patel held key leadership positions in the telecommunications industry, semiconductor capital equipment industry, wireless industry and information technology industry. His experience includes Lean Six Sigma, creating long and short- term strategy, influencing organizational change, modernizing government systems, and delivering high technology products and services in fast-paced, technology-intensive organizations. Mr. Patel earned an MS in Electronic Systems Engineering from the University of Regina, Canada, and an MBA in International Business from The Johns Hopkins University.
Dr. Gandhi is a Principal at Longwood Fund, where he creates and invests in science-based companies that develop novel solutions for major medical problems. Prior to Longwood, he was an attending hospitalist at the Massachusetts General Hospital, where he also trained as a resident physician in internal medicine. He previously held an investing role at Excel Venture Management, where he evaluated early-stage biopharmaceutical and healthcare IT investments, an operating role at Wellable, where he helped to build a mobile corporate wellness startup as its Chief Medical Officer, and consulting roles at McKinsey & Company and the TriZetto Corporation. He holds an M.D. from Harvard Medical School, an M.B.A. from Harvard Business School, where he was a Baker Scholar, a D.Phil. in medical oncology from the University of Oxford where he was a Rhodes Scholar, and a B.S. with honors in biochemistry from Case Western Reserve University. He is the Secretary/Treasurer of the Suffolk District Medical Society, the professional medical society of Boston, and is a past trustee of the Massachusetts Medical Society and Boston Medical Library.
Former Managing Director at Opus Point Partners which created, financed, & operated 10+ science companies including Cougar Biotechnology (CGRB), Chelsea Therapeutics (CHTP), TG Therapeutics (TGTX), Assembly Biosciences (ASMB), Tracon Pharmaceuticals (TCON), Fortress Biotech (FBIO), and Ziopharm Oncology (ZIOP)
Co-Founder & Owner at Klein Sun Gallery, America's leading Chinese contemporary art gallery
Guest Lecturer, Biotechnology Program at Columbia University & 17+ years life science industry experience
Former Senior Consultant at Pfizer & Strategic Advisor at publicly traded & privately held life science companies
B.A., Brandeis University
Co-Founder & Owner at Klein Sun Gallery, America's leading Chinese contemporary art gallery
Guest Lecturer, Biotechnology Program at Columbia University & 17+ years life science industry experience
Former Senior Consultant at Pfizer & Strategic Advisor at publicly traded & privately held life science companies
B.A., Brandeis University
David Amor is an FDA/ EU Quality/ regulatory expert focused on combination products and digital health. From NDAs and 505(b)(2)s to mobile app 510(k)s and Pre-INDs/ Q-subs, David has worked with over 45 medical device and pharmaceutical companies – large and small alike- supporting and/ or leading regulatory submissions and implementing quality management systems, including alignment of Agile-based SDLC programs to FDA and EU requirements. He co-founded RemindTrac in 2014 (www.remindtrac.com), a digital health company for chronic patients, that continues to pioneer mobile care management systems today, and sold his consulting firm Medgineering in 2016.
David has recently led QA/RA strategy groups at Teva within the Digital Health Group, particularly in development of Agile-based Quality Management Systems, was a Principal Consultant in the CP/DH (Combination Products, Digital Health) group at Qara Partners, and served as the in-house risk management subject matter expert at Abbott (St. Jude Medical). He has served as the Director or VP of Quality at other medical device start-ups including AdrenaCard, Calcula, Enspero Medical and various others, and led multiple organizations through 483 and Warning Letter remediation projects, namely associated with risk management and design history file deficiencies, including Pfizer (Hospira), MID, Boston Scientific and St. Jude Medical.
Matthew Tucker helps healthcare companies solve complex commercial problems so they can grow bigger and faster. With extensive experience leading commercial planning and execution across functional areas, Mr. Tucker has leveraged his leadership roles at Highmark Health, Baxter, Mylan, and a number of startups. Over the course of his career, he has led significant growth in health plan initiatives and of more than 20 medical device and pharmaceutical brands.
Megan Coder, PharmD, MBA, is Executive Director of the Digital Therapeutics Alliance. DTA’s mission is to broaden the understanding, adoption, and integration of clinically-validated digital therapeutic solutions into mainstream healthcare through education, advocacy, and research.
With more than a decade of experience in the healthcare industry, Megan’s expertise extends from strategic growth and partnership development within the digital health sector, to the direct delivery of patient care. Prior to joining DTA, Megan worked with Voluntis, Iodine, the Pharmaceutical Care Management Association, and the Pharmacy Technician Certification Board.
A proud Badger, Megan graduated from the University of Wisconsin—Madison School of Pharmacy and completed an Executive Residency in Association Management & Leadership with the American Pharmacists Association.
Edward Cox was appointed as the new Chairman of the Board and the Chief Executive Officer of Dthera in connection with the closing of the EveryStory Transaction. Mr. Cox also continues to serve as EveryStory’s President and Chief Executive Officer and Chairman and a member of EveryStory’s Board of Directors, positions he has held since February 6, 2015. Prior to that, he served as a Vice President and Executive Officer of Apricus Biosciences, Inc., a publicly traded company, since December 2009, in roles leading Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.
Mark Bini is the Vice President of Innovation and Member Experience at Express Scripts. Since 2008, Mark has been a key contributor to the advancement of Express Scripts’ solution portfolio. Over this time, he has worked with other thought leaders to design and employ an industry-leading, behavior-centric approach to innovation that places clients and members in the “front seat” of product development. Mark is also responsible for Express Scripts’ suite of digital therapeutic solutions that includes remote monitoring solutions for diabetes, asthma, and medication non-adherence. Mark’s approach to innovation and the solutions that have spawned from it have played a key role in Express Scripts being named to Forbes’ World’s Most Innovative Companies.
Jim has over 25 years of experience harnessing innovative technologies to solve important biological measurement problems.
Shortly after joining PureTech Health in 2015, he co-founded Sonde Health to provide high-frequency clinical-grade health measurements of health and disease using voice analysis on devices that people already own. He was previously with MIT Lincoln Laboratory where he worked for 15 years to help grow new biotechnology and bioengineering capabilities and teams.
Dr. Harper received his BS in biochemistry from Furman University, his PhD in biochemistry from MIT, and was a postdoctoral research fellow at Harvard Medical School in the Center for Neurologic Diseases.
Eddie co-founded Akili Interactive Labs, and as part of PureTech has co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City, MO, focused on healthcare entrepreneurship. Prior to that, he completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry, focusing on structure-based drug design, where he led a research project that identified two novel chemical scaffolds as proof-of-concept compounds for novel therapy. Eddie received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University.
Ken is a regulatory affairs and business development lead at CureApp North America. He is specialized in US regulatory compliance with a strong engineering background. Before joining CureApp, he worked for regulatory compliance and business consulting company where he completed more than 14 regulatory submissions ranging from De Novo and 510(k) to Q-subs (Pre-sub, submission issue, supplemental) and variance requests.
With a variety of regulatory submission experience for products from early to late stages of development, he is currently responsible for CureApp's US regulatory compliance, acting as a vital liaison between Japanese and US regulatory agencies.
In Japan, CureApp recently completed a phase III clinical trial and regulatory submission to the Japanese PMDA for a smoking cessation app. CureApp would like to share insights from outside of the US regulatory environment at the DTx East meeting.
Owen is the co-founder and President of MedRhythms Inc., which he intends to lead with compassion and a commitment to excellence. He is determined to provide patients across the globe with the services necessary to recover their walking ability and regain their independence. Owen started MedRhythms as an experienced entrepreneur with a MBA degree from Harvard Business School.
Anil is a physician executive based in the Boston area and has over 20 years of global healthcare and biopharmaceutical experience. He studied medicine in Ireland and worked clinically in the Irish healthcare system before moving to the biopharmaceutical industry where he has held roles of increasing responsibility across different companies, different therapeutic areas and different geographies.
Anil's interest in developing world healthcare started while he was studying medicine at the Royal College of Surgeons in Ireland, where he raised money to purchase medical supplies for a rural health clinic in Tanzania, East Africa, and delivered them personally as well as working in the clinic for 3 months. More recently he has been instrumental in establishing a charitable access program to rare disease medicines which is now operating across 10 countries.
Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations. He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals. Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.
Chuck Gammal is a Partner within the Life Sciences division at Simon-Kucher. Chuck’s focus is on helping clients navigate the challenges of developing sustainable digital businesses.
Specifically, Chuck helps digital health, medical technology, and pharmaceutical clients identify and deploy the optimal commercial model to monetize innovation.
Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University
Kristine leads the National Healthcare Practice at Michael Best Strategies. Previously, she was the RVP of Market Development for Humana. Kristine works with healthcare start-ups focusing on tactical execution in the commercialization of their company with a focus on revenue and growth. She leverages her expansive connections in the C-suite of national payers, providers, governmental agencies and employer coalitions to bring innovation to the healthcare ecosystem while focusing on the ROI.
Summit Workshops
Day 1: September 24th
Click to download our full event agenda.
Workshop Leaders to be Announced
9:00 am Presentation: What does the Digital Therapeutics Industry Look like Today?
- How has the digital therapeutics industry got to this point in its history?
- What are the current definitions and main sectors involved in digital therapeutic development and adoption?
9:30 am Breakout Discussions:
Splitting into smaller working groups, each group will discuss their current views on digital therapeutics, as well as their views on fundamentals of the industry.
10:30 am Refreshment Break
11:00 am Feedback Discussions
Representative(s) from each group share the main points from their discussion to the whole group. Additional questions from moderators and other group members will be raised during this collaborative discussion.
Leave this workshop with:
- A clear understanding of the defining characteristics of a digital therapeutics and the sub-categories emerging
- A deeper understanding of the leading routes to markets and partnership models for digital therapeutic commercialization
- Up-to-date information on where digital therapeutics are already having a significant impact in healthcare
- A stronger appreciation of the crucial questions facing the industry that will be tackled during the rest of the Summit.
- Your questions answered by industry leading experts and your peers
12:00 pm End of Workshop 1
Workshop Leader:
David Amor, Vice President, Quality & Regulatory Affairs, Pear Therapeutics
Kenichiro Nishii, Lead, Regulatory Affairs & Business Development, CureApp
1:00 pm Presentation: What does the Current Digital Health Regulatory Landscape Look Like?
- What have been the crucial advancements for digital health regulation?
- In relation to Digital Therapeutics, what are we anticipating the next updates in regulation to entail?
- How are OUS regulators addressing digital therapeutics?
1:30 pm Breakout Discussions
Splitting into smaller working groups, each group will discuss the crucial sub-topics of digital health regulation, as they relate to digital therapeutics specifically…
2:30 pm Refreshment Break
3:00 pm Feedback Discussions
Representative(s) from each group share the main points from their discussion to the whole group. Additional questions from moderators and other group members will be raised during this collaborative discussion.
Leave this workshop with:
- A clear understanding of the current digital health regulatory landscape
- A deeper understanding of how regulation is impacting digital therapeutics
- Up-to-date information on what we are anticipating the next series of updates from regulators to look like
- A stronger appreciation for the more emerging topics of regulation, such as AI and real time data analysis
- Takeaway lessons learned that relate to the level of regulation required for your product(s)/work.
4:00 pm End of Workshop 2
Summit Agenda
Click to download our full event agenda.
Registration & Networking Evening
4:30 pm Registration
Registration is open for all summit attendees ahead of the networking evening.
DTx Networking
Networking is an integral part of the DTx Series, which is why there is now more time solely dedicated to it.
Utilizing a variety of formats, attendees will be able to make dozens of new connections, meet industry leaders and catch-up with old friends. Immerse yourselves in the digital therapeutics community!
5:30 pm Speed Networking
The goal of this session is to meet with as many people as possible in just 40 minutes.
Introduce yourself to each person around your table, swap business cards and plan to meet up later on.
It’s all about the quantity of connections at this stage!
6:10 pm 1-2-1 Meetings
Use this dedicated meeting time to catch up with old friends and new connections you have just made, or planned to meet up with during the event.
Space will be set aside for more private conversations, as well as more organic networking to ensure that you meet everyone you want.
7:00 pm Networking Drinks
After an intense couple of hours of networking, unwind with your peers over a drink or two!
8:00 am Breakfast & Networking
9:00 am Chair’s Opening Remarks & Setting the Scene
Jeffrey Abraham, Vice President, Market Access & Trade, Akili Interactive
Digital Therapeutics: Going Beyond the Headlines
9:15 am Presentation – Digital Health Regulation, Pre-Cert Program as they Relate to Digital Therapeutics
Bakul Patel, Director, Division of Digital Health, FDA
9:45 am Keynote Panel – What is Keeping you up at Night about Digital Therapeutics?
Megan Coder, Executive Director, Digital Therapeutics Alliance
David Klein, Co-Founder & Chief Executive Officer, Click Therapeutics
Eddie Martucci, Co-Founder & Chief Executive Officer, Akili Interactive
Alex Waldron, Chief Strategy Officer, Pear Therapeutics
Chuck Gammal, Partner, Simon-Kucher & Partners
10:45 am Morning Refreshments & Networking
Day 2 will now split into two tracks
Track 1
Routes to Market for Digital Therapeutics
Chair: Jeffrey Abraham, Vice President, Market Access & Trade, Akili Interactive
11:30 am Presentation – How to Partner with Self-Insured Employers
Dannielle Sherrets, Director, Health Innovations & Special Projects, National Business Group on Health
11:55 am Presentation – Breaking Down Silos: Why Digital Health Solutions Need the Ecosystem to Succeed
Speaker to be confirmed, BrightInsight, a Flex Company
Track 2
Showcases & Crucial Considerations
Chair: Ed Cox, Chief Executive Officer, Dthera Sciences
11:30 am Presentation – Forging Hope Against in the Fight Against Alzheimer’s Disease through Digital Therapeutics
Elli Kaplan, Chief Executive Officer, Neurotrack
11:55 am Presentation – Applying Novel Evidence Generation Techniques to Digital Therapeutics Development
Speaker to be confirmed, IQVIA
12:20 pm Lunch & Networking
2:00 pm Fireside Chat and Open Q&A – Integration of Digital Therapeutics in Novartis/Sandoz
Andre Heeg, Head of Digital, Sandoz
Joris van Dam, Executive Director, Head of Digital Therapeutics, Novartis
2:45 pm Panel – Pharma and DTx Partnerships – A Match Made in Heaven?
Spencer Jones, Vice President, Global Medical Affairs, Sandoz
Bozidar Jovecevic, Vice President, Global Head of Digital Therapeutics, Sanofi
Georgia Misti, Senior Director, Frontier Business, Sunovion Pharmaceuticals
2:00 pm Panel – What Level of Clinical Evidence is Required for Digital Therapeutics?
Anil Jina, Chief Medical Officer, Akili Interactive
Jo Masterson, Chief Product Officer, 2Morrow Inc
Acacia Parks, Chief Scientist, Happify Health
2:45 pm Panel – Providers Perspectives: How do Digital Therapeutics need to Adapt to Fit into Healthcare Systems?
Yvonne Yu-Feng Chan, Director, Center for Digital Health, Icahn School of Medicine at Mount Sinai
Dan Henderson, Primary Care Physician, Massachusetts General Hospital
3:30 pm Afternoon Refreshments & Networking
4:00 pm Panel – What Should the Infrastructure Look like to get Digital Therapeutics to Patients?
Timothy Aungst, Associate Professor, Pharmacy Practice, MCPHS University
Crystal Broj, Chief Technology & Digital Officer, American Association of Diabetes Educators
Patricia Simon, Director, Innovation Impact, Yale School of Medicine
4:45 pm Panel – Digital Therapeutics Commercialization: Lessons Learned from the Front Line
Peter Hames, Co-Founder & Chief Executive Officer, Big Health
Debra Reisenthel, Founding Chief Executive Officer, Palo Alto Health Sciences
4:00 pm Presentation – Voice-based Technology – The Next Generation of Digital Medicine?
Jim Harper, Co-Founder & Chief Operating Officer, Sonde Health
4:25 pm Panel – What do Digital Therapeutic Companies Need to Demonstrate when Looking to Secure Investment?
Pavan Choski, Investment Associate, Arkitekt Ventures
Shaan Gandhi, Principal, Longwood Fund
Chihiro Hosoya, BD / VC Head, Rx+ Business Accelerator, Astellas Venture Management
Zack Lynch, Managing Partner, JAZZ Venture Partners
5:30 pm Drinks Reception
Download the agenda to access full details…
8:00 Breakfast & Networking
9:00 Chair’s Opening Remarks
Adam Kaufman, Chief Executive Officer, Canary Health
9:10 Presentation – 8 Weeks, 4 Consultants, 1 Company: Insights and Results from the DTx East Slingshot
Michael Lieberman, PhD, Senior Vice President, Medical Sciences, Klick Consulting
Jennifer White, Senior Vice President, Strategic Partnerships, Klick Consulting
Reimbursing and Scaling Digital Therapeutics
9:35 Panel – The Reimbursement Landscape for Digital Therapeutics
Moderator: Pierre Leurent, Chief Executive Officer, Voluntis
Mark Bini, Vice President, New Solutions, Express Scripts
Sukanya Soderland, Chief Strategy Officer, Blue Cross Blue Shield Massachusetts
Matthew Tucker, Executive Director, Strategy & Transformation, Highmark Health
10:20 Panel – The Digital Therapeutics Engagement Chain
Moderator: Anand Iyer, Chief Strategy Officer, Welldoc
Anton Decker, President, Health Innovation, Bon Secours Mercy
Scott DeMario, HR Benefits Consultant, CUNA Mutual Group
Tammi Grumski, Diabetes Program Director, UPMC Health Plan
Dan Henderson, Primary Care Physician, Massachusetts General Hospital
Kristine Seymour, Partner, Michael Best Strategies
11:05 Morning Refreshments & Networking
Digital Therapeutics Showcase
11:30 Presentation – How to Build and Scale Digital Therapeutics in Emerging Markets
Abhishek Shah, Co-Founder & Chief Executive Officer, Wellthy Therapeutics
11:55 Presentation – The Role of Digital Therapeutics in the Consumerization of Health
Erez Raphael, Chief Executive Officer, Dario Health
12:20 Presentation – Presentation by Ieso Digital Health
Andy Blackwell, Chief Scientific Officer, Ieso Digital Health
12:45 Lunch & Networking
2:00 Panel – What do we do Great and What do we Need to Get Better at as an Industry?
Mette Dyhrberg, Founder & Chief Executive Officer, Mymee
Owen McCarthy, Co-Founder & President, MedRhythms
Pablo Pantaleoni, Vice President & General Manager, Headspace
2:45 Chair’s Summary
Adam Kaufman, Chief Executive Officer, Canary Health
2:50 Close of DTx East 2019
Download Agenda to access full details of the event…
DTx East Venue 2019
Joseph B. Martin Conference Centre
At Harvard Medical School
The 2nd Annual Edition of DTx East is being held within the New Research Building at Harvard Medical School, The Joseph B. Martin Conference Center.
Located in the heart of Boston’s Longwood Medical Area, Harvard Medical School offers a new standard of excellence.
With beautifully designed warm wood interior, comfortable seating, excellent acoustics and visuals, plus generous networking space, a visit to this impressive venue will certainly be a memorable experience.
More details about the venue and nearby accommodation will be included in your welcome pack.
Registration
Partnerships
The DTx summits are the home for the key decision makers in the rapidly growing Digital Therapeutics industry to meet, learn and connect.
All of the relevant companies are represented, from pioneers such as Akili, Pear and Dthera to big pharma including Sanofi, Novartis and Sandoz.
DTx East is the 5th event in the series, and the second time we are hosting the event in Boston, MA. The programme is bigger and better than ever before, spanning 3 days.
7 Sponsors and supporters are already confirmed at launch and we have a limited number of spaces left for forward-thinking companies who want to get involved with this senior-level audience.
To discuss options available, or to learn more about the event please get in touch.
Contact Sam Confino via email: sam@greygreenmedia.com
Contact Us
